Product Description: RO8994 (Compound 4) is an orally active, highly potent and selective spiroindolinone p53-MDM2 inhibitor with an IC50 value of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays). RO8994 induces up-regulation of p53 expression and Apoptosis in wild-type p53 cancer cells. RO8994 also inhibits tumor growth in the tumor xenograft model[1][2][3].
Applications: Cancer-programmed cell death
Formula: C31H31Cl2FN4O4
References: [1]Zhang Z, et al. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorg Med Chem. 2014 Aug 1;22(15):4001-4009./[2]Zhang Z, et al. Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development. ACS Med Chem Lett. 2013 Dec 29;5(2):124-7./[3]Yu B, Liu H M. The development of new spirooxindoles targeting the p53–MDM2 protein-protein interactions for cancer therapy[J]. Targeting Protein-Protein Interactions by Small Molecules, 2018: 213-237.
CAS Number: 1309684-94-3
Molecular Weight: 613.51
Compound Purity: 99.62
Research Area: Cancer
Solubility: DMSO : ≥ 45 mg/mL
Target: Apoptosis;E1/E2/E3 Enzyme;MDM-2/p53
English
Deutsch
